In Orthopedics, Consolidation's Aftershocks

Following significant consolidation in 1998, orthopedic industry executives are bracing for more deal-making. A handful of deals in 1999 suggest continued consolidation, but the modesty of the deals also implies that consolidation is unlikely at such an aggressive pace.

Even after the tremendous consolidation of 1998, many orthopedic industry executives are betting on more. The big deals will likely involve Bristol-Myers Squibb Co. subsidiary Zimmer Inc., widely rumored to be on the block, and either Smith & Nephew PLC or Sulzer Medica Ltd. , two companies in the middle of the market-share pack who have made clear their intentions to grow their orthopedic businesses, particularly in total joints. Another possible consolidation player: spinal company Surgical Dynamics Inc. , now a Tyco International Ltd. business after that company's acquisition last year of United States Surgical Corp.[See Deal]. Tyco officials have hinted that they will either have to significantly increase their presence in orthopedics or get out altogether, because holding on with a single orthopedic business isn't viable.

Until those bigger deals take place, however, what deal-making occurs in orthopedics is likely to be small, such as Encore...

More from Business Strategy

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By 

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

AI In Drug Discovery: The Patent Implications

 
• By 

A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.

Is Advanced AI Revolutionizing Sales Enablement In Pharma?

 
• By 

Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.

More from In Vivo

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By 

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By 

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.